Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Transcript Of Conference Call With Analysts / Investors On Financial Results For The Quarter And Half Year Ended 30Th September, 2022

 In continuation of our letter dated 14-Oct-22 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Transcript of Conference call with Analysts / Investors on Financial Results of the Company for the quarter and half year ended 30th September, 2022, has been placed on the Company's website at: https://www.torrentpharma.com/pdf/investors/TorrentPharma_Earnings_Q2_2022_23.pdf
28-10-2022

Buy Torrent Pharmaceuticals; target of Rs 1820: Sharekhan

 Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1820 in its research report dated October 25, 2022.
27-10-2022

Buy Torrent Pharmaceuticals; target of Rs 1850: Prabhudas Lilladher

 Prabhudas Lilladher is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated October 25, 2022.
25-10-2022

Torrent Pharma Consolidated September 2022 Net Sales at Rs 2,291.00 crore, up 7.21% Y-o-Y

 NULL
25-10-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Audio Recording Of Conference Call With Analysts / Investors On Financial Results For The Quarter And Half Year Ended 30Th September, 2022

 In continuation of our letter dated 14-Oct-22 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of Conference call with Analysts / Investors on Financial Results of the Company for the quarter and half year ended 30th September, 2022, has been placed on the Company's website at https://www.torrentpharma.com/pdf/investors/Audio_Recording30092022.mp3
21-10-2022

Torrent Pharma Q2 net profit declines to Rs 312 crore

 Revenue from operations rose to Rs 2,291 crore in the July-September quarter as against Rs 2,137 crore in the year-ago period, Torrent Pharma said in a statement.
21-10-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Compliance As Per Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
21-10-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Submission / Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

 Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
21-10-2022
Bigul

Q2FY23 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.

 Torrent Pharmaceuticals announced Q2FY23 results: Revenue at Rs 2,291 crore up by 7%. Gross margins: 72%; EBITDA margins: 30%. EBITDA at Rs 694 crore was down by 2%. Net profit after tax at Rs 312 crore was down by 1%. Result PDF
21-10-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2022
21-10-2022
Next Page
Close

Let's Open Free Demat Account